Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
Structure Therapeutics Inc. - American Depositary Shares (GPCR)
Company Research
Source: GlobeNewswire
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671) Phase 1 study initiation anticipated by year-end 2025; second oral amylin receptor agonist (ACCG-3535) development candidate declared Strong financial position with cash, cash equivalents and short-term investments of $799.0 million as of September 30, 2025 SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “We are on schedule to report topline data by year-end 2025 from both the ACCESS and ACCESS II studies of aleniglipron, our once-daily oral small molecule GLP-1 receptor ago
Show less
Read more
Impact Snapshot
Event Time:
GPCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GPCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GPCR alerts
High impacting Structure Therapeutics Inc. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GPCR
News
- Structure Therapeutics (NASDAQ:GPCR) was given a new $50.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Structure Therapeutics (NASDAQ:GPCR) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- BMO Capital Remains Bullish on Structure Therapeutics (GPCR), Cites Upcoming Trial Readouts [Yahoo! Finance]Yahoo! Finance
- Structure Therapeutics (NASDAQ:GPCR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
GPCR
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- GPCR's page on the SEC website